Jeito
  • About
  • The team
  • Our portfolio
  • ESG & Impact
  • Newsroom
  • Contact
  • English
    • Français
    • English
Select Page

Jeito Capital Portfolio Company Odyssey Therapeutics Successfully Completes Upsized IPO on NASDAQ, Raising a Total of $304 million

by Manon FRACHON | 12 May Tue | Without category

Jeito[1] reaffirms its commitment by participating in the IPO, following its significant investment in Odyssey’s recent oversubscribed $213 million series D financing round This renewed support underscores the company’s innovation potential for patients with...

Jeito Capital appoints Samit Hirawat, M.D., as Strategic Medical Advisor to strengthen Jeito’s leadership in driving innovations for patient benefit

by Manon FRACHON | 11 Mar Wed | Without category

Samit Hirawat, M.D., brings over 25 years of senior leadership and clinical development experience at top-tier international pharmaceutical groups, including Novartis and Bristol Myers Squibb, further enhancing Jeito’s strategic capabilities. His expertise will...

Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million

by Manon FRACHON | 24 Feb Tue | Without category

Proceeds from the financing will advance the Phase 2 clinical development of Alveus’ lead program ALV‑100 designed to deliver potent, durable weight loss and long‑term maintenance with improved tolerability. The financing will also support Investigational New Drug...

Recent Posts

  • Jeito Capital Portfolio Company Odyssey Therapeutics Successfully Completes Upsized IPO on NASDAQ, Raising a Total of $304 million
  • Jeito Capital bolsters its leadership team with the appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent
  • Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC Pipeline in Oncology
  • Jeito Capital hits record $1.2 billion (€1 billion) close for Jeito II Fund to drive breakthrough therapeutic innovation for patients
  • Jeito Capital appoints Samit Hirawat, M.D., as Strategic Medical Advisor to strengthen Jeito’s leadership in driving innovations for patient benefit

Recent Comments

    Mentions et autres liens
    We use cookies to provide you with the best possible website experience by
    offering you tailored content and for statistical purposes. You can modify your
    choices at any time. For more information, please consult our cookie policy.
    Cookie settingsAccept allReject all
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while browsing the site. Among these, cookies that are categorized as necessary are stored on your browser as they are essential for the basic functionality of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option to decline these cookies. However, disabling some of these cookies may affect your browsing experience.
    Necessary
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    SAVE & ACCEPT